Value
7.4/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 4.5 |
| Fwd P/E | 8.8 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 12.6x
- ▸PEG: 0.05
- ▸Attractively valued
URGN · Why this verdict
Why UroGen Pharma (URGN) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.4/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
UroGen is a speculative biotech with revenue growing about 199% year over year and 59.5% upside to the analyst target, but it still burns cash, depends on two products and faces earnings in three days with insiders selling.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quarterly revenue reached $72.5M for the period ended 2026-06-30 versus $24.2M a year earlier, consistent with 199% YoY growth. Revenue quarters | Quarterly revenue continues toward the $89.8M next-quarter estimate and stays above $70M over 12 months. | ↑Improving |
| CounterLaunch-phase revenue can plateau once initial patient demand is served, and sequential growth could stall. | ||
The company is still cash-burning, with free cash flow at -57% of revenue, so the thesis depends on revenue growth outpacing spending. Quality breakdown | Free cash flow burn narrows well below 57% of revenue as revenue scales over 12 months. | →Stable |
| CounterContinued commercial launch spending and losses per share of -$0.28 could force dilutive financing before profitability. | ||
The $52.20 analyst target implies 59.5% upside from $32.72, with a reward-to-risk ratio of 5.76 against about 10% downside. Analyst target | The price moves toward the analyst target as revenue growth is confirmed over the next 12 months. | ↑Improving |
| CounterAnalyst coverage is light, so the target carries less weight, and the stock has weak momentum and falling on-balance volume. | ||
Revenue depends on Jelmyto and Zusduri, so a setback in either product would hit the whole growth story. Bear case | Zusduri uptake keeps diversifying revenue so that no single product exceeds 80% of sales within 12 months. | ↑Improving |
| CounterWith only two products, competition, reimbursement changes or label issues could quickly reverse the revenue ramp. | ||
Insiders sold about $3.0M of stock in 90 days with no buys, while earnings are due in 3 days and the company missed estimates in 2 of the last 4 quarters. Insider | Insider net selling stays small and EPS comes in at or above estimates in the coming reports. | →Stable |
| CounterThe insider sales equal only 0.19% of market cap and may be routine; recent EPS misses were only a few percent. | ||
Quarterly revenue reached $72.5M for the period ended 2026-06-30 versus $24.2M a year earlier, consistent with 199% YoY growth.
↑ImprovingRevenue quarters
- Expectation
- Quarterly revenue continues toward the $89.8M next-quarter estimate and stays above $70M over 12 months.
CounterLaunch-phase revenue can plateau once initial patient demand is served, and sequential growth could stall.
The company is still cash-burning, with free cash flow at -57% of revenue, so the thesis depends on revenue growth outpacing spending.
→StableQuality breakdown
- Expectation
- Free cash flow burn narrows well below 57% of revenue as revenue scales over 12 months.
CounterContinued commercial launch spending and losses per share of -$0.28 could force dilutive financing before profitability.
The $52.20 analyst target implies 59.5% upside from $32.72, with a reward-to-risk ratio of 5.76 against about 10% downside.
↑ImprovingAnalyst target
- Expectation
- The price moves toward the analyst target as revenue growth is confirmed over the next 12 months.
CounterAnalyst coverage is light, so the target carries less weight, and the stock has weak momentum and falling on-balance volume.
Revenue depends on Jelmyto and Zusduri, so a setback in either product would hit the whole growth story.
↑ImprovingBear case
- Expectation
- Zusduri uptake keeps diversifying revenue so that no single product exceeds 80% of sales within 12 months.
CounterWith only two products, competition, reimbursement changes or label issues could quickly reverse the revenue ramp.
Insiders sold about $3.0M of stock in 90 days with no buys, while earnings are due in 3 days and the company missed estimates in 2 of the last 4 quarters.
→StableInsider
- Expectation
- Insider net selling stays small and EPS comes in at or above estimates in the coming reports.
CounterThe insider sales equal only 0.19% of market cap and may be routine; recent EPS misses were only a few percent.
Per-dimension breakdown
Quality
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.1 |
| Net margin | 0.0 |
| Current ratio | 9.2 |
| FCF quality | 0.0 |
| Moat | 7.0 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -57% of revenue
- ▸Rule of 40: 143 (elite)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 199% YoY
Momentum
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.5 |
| MACD | 6.3 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 8.3 |
- ▸Uptrend pullback (RSI 30) - buy opportunity
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.8 |
| Analyst rating | 7.9 |
| Price target | 9.9 |
- ▸LLM news sentiment: +0.36 (n=4)
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 75%
Insider
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 6.8 |
| notable moves | 7.0 |
- ▸Notable insider selling — $3,037,646 (0.190% of mkt cap)
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.5 |
| quality rank | 2.0 |
| growth rank | 9.2 |
- ▸Industry growth leader
Technical
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.6 |
| support resistance | 8.2 |
| 52w position | 3.5 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.2 |
| days to cover | 4.6 |
| volatility | 0.0 |
| put call | 7.9 |
| implied vol | 0.0 |
| beta | 4.7 |
| news risk | 6.0 |
- ▸High IV: 113%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 1.5 |
| news activity | 8.0 |
- ▸Earnings concerns: 1B/2M
- ▸Earnings in 1 day
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position.
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULTPassed (4)
- MOMENTUM:5.6>=5.5
- ASYMMETRY:5.1>=1.5
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:1d<=7d
Warning (2)
- INSIDER:0.19%=MODERATE
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
5.08
Upside
+51.9%
Downside
10.2%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: MOMENTUM:5.6>=5.5. Top dim: Growth at 10.0; weakest: Risk (lower is worse) at 3.9. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Growth at 10.0, Sentiment at 8.1, and Value at 7.4; the weakest are Risk (lower is worse) at 3.9, Catalyst at 4.4, and Insider at 4.7. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 5.08 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Rapid Revenue Ramp
Trip ifQuarterly revenue falls below $60M for 2 consecutive quarters.
- P2Cash Burn Narrowing
Trip ifFree cash flow burn widens to more than 80% of revenue.
- P3Analyst Target Upside
Trip ifAnalyst target falls below $36 from the current $52.20.
- P4Two Product Concentration
Trip ifA single product exceeds 90% of quarterly revenue.
- P5Insider Selling Before Earnings
Trip ifInsider net selling exceeds $6M over 90 days.